The 10 latest articles on Research and Innovation come from 8 sources, published between Nov 10 and Nov 12. Most come from BIOENGINEER.ORG (3).
People in these stories: Wang (2), Chakraborty (2), Ke (2), Yang (2)
Organizations: National Institutes of Health (2)
Places: Australia (2), U.S. (2)
Published: November 10 2026 Last updated: November 10 2026 Kami Kountcheva | An experimental gene therapy has been trialled in three adults, with early findings showing few side effects and more than 90% reduction in seizures. An experimental new gene therapy is showing promising results in…
Our goal is using this scientific research to make a meaningful difference.”.(KAUZ) By Hunter DoughtyPublished: Nov. 12, 2026 at 5:00 PM CST|Updated: 30 minutes agoAdd Us On GoogleAdd as a preferred source on GoogleWICHITA FALLS, Texas (KAUZ) - A Midwestern State University professor…
Robert Josephs, PhD, a Professor Emeritus in the Department of Molecular Genetics and Cell Biology who served on the faculty at the University of Chicago for more than 46 years, died on September 19, 2026. He was 89 years old. Josephs was a structural…
Back to lifespan Home Login Return to Lifespan Homepage Donate Login Donate A New Target for Fighting Tau Tangles in Neurons This biochemical complex may play a significant role in Alzheimer's. by Josh Conway November 12, 2026 HDAC7 encourages the stabilization and activation…
Home / News / ‘Epigenetic age’ may help predict lung cancer survival, influence treatment Cancer ‘Epigenetic age’ may help predict lung cancer survival, influence treatment By Karen Feldscher November 12, 2026 Fetrinka / iStock Predicting survival among early-stage non-small cell lung cancer (NSCLC) may be…
Key Takeaways Moderna said on Nov. 6 that it and Merck plan to file intismeran, which cut melanoma recurrence or death risk 42% with Keytruda, this year. Merck splits intismeran’s profits with Moderna, and approval is only hoped for in 2027, so the…
Live feedPRReleasevia QuantisnowZealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits ByQuantisnow·Nov 9, 2026 · 09:45:00 ET·Wall Street's wire, on your screen.
What the labs are producing.
An article joins this feed when it matches these terms. Each one is also a search of its own.